Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.12.7719

siRNA-mediated Silencing of Survivin Inhibits Proliferation and Enhances Etoposide Chemosensitivity in Acute Myeloid Leukemia Cells  

Karami, Hadi (Immunology Research Center, Tabriz University of Medical Sciences)
Baradaran, Behzad (Immunology Research Center, Tabriz University of Medical Sciences)
Esfahani, Ali (Hematology and Oncology Research Center, Tabriz University of Medical Sciences)
Estiar, Mehrdad Asghari (Scientific Research Center, Tehran University of Medical Sciences)
Naghavi-Behzad, Mohammad (Medical Philosophy and History Research, Tabriz University of Medical Sciences)
Sakhinia, Masoud (Faculty of Medicine, University of Liverpool)
Sakhinia, Ebrahim (Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.12, 2013 , pp. 7719-7724 More about this Journal
Abstract
Background: Overexpression of survivin, a known inhibitor of apoptosis, is associated with tumor progression and drug resistance in numerous malignancies, including leukemias. The aim of this study was to investigate the effect of a specific survivin small interference RNA (siRNA) on proliferation and the sensitivity of HL-60 acute myeloid leukemia (AML) cells to the chemotherapeutic drug etoposide. Materials and Methods: The cells were transfected with siRNAs using Lipofectamine $^{TM}2000$ transfection reagent. Relative survivin mRNA and protein levels were measured by quantitative real-time PCR and Western blotting, respectively. Trypan blue exclusion assays were performed to monitor tumor cell proliferation after siRNA transfection. The cytotoxic effects of etoposide and survivin siRNA, alone and in combination, on leukemic cells were determined using MTT assay. Apoptosis was assessed by ELISA cell death assay. Results: Survivin siRNA markedly reduced both mRNA and protein expression levels in a time-dependent manner, leading to distinct inhibition of cell proliferation and increased spontaneous apoptosis. Surprisingly, survivin siRNA synergistically increased the cell toxic effects of etoposide. Moreover, survivin down-regulation significantly enhanced its induction of apoptosis. Conclusions: Our study suggests that down-regulation of survivin by siRNA can trigger apoptosis and overcome drug resistance of leukemia cells. Therefore, survivin siRNA may be an effective adjuvant in AML chemotherapy.
Keywords
Survivin; siRNA; etoposide; HL-60; apoptosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Adida C, Recher C, Raffoux E, et al (2000). Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol, 111, 196-203.   DOI   ScienceOn
2 Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K (2003). RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol, 30, 96-102.   DOI   ScienceOn
3 Baran Y, Gur B, Kaya P, et al (2007). Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematol, 12, 511-7.   DOI   ScienceOn
4 Brantl S (2002). Antisense-RNA regulation and RNA interference. Biochim Biophys Acta, 1575, 15-25.   DOI   ScienceOn
5 Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55.   DOI   ScienceOn
6 Church DN, Talbot DC (2012). Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep, 14, 120-8.   DOI   ScienceOn
7 Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH (2013). Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev, 39, 802-11.   DOI   ScienceOn
8 Dai Y, Grant S (2007). Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res, 67, 2908-11.   DOI   ScienceOn
9 Devi GR (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther, 13, 819-29.   DOI   ScienceOn
10 Feng W, Yoshida A, Ueda T (2013). YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun, 435, 52-7.   DOI   ScienceOn
11 Fukuda S, Pelus LM (2006). Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther, 5, 1087-98.   DOI   ScienceOn
12 Gautrey HL, Tyson-Capper AJ (2012). Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One, 7, 51497.   DOI
13 High LM, Szymanska B, Wilczynska-Kalak U, et al (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol, 77, 483-94.   DOI   ScienceOn
14 Ho MM, Hogge DE, Ling V (2008). MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol, 36, 433-42.   DOI   ScienceOn
15 Kang MH, Reynolds CP (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 15, 1126-32.   DOI   ScienceOn
16 Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011). Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer, 10, 35.   DOI   ScienceOn
17 Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods, 25, 402-8.   DOI   ScienceOn
18 Martins LM, Mesner PW, Kottke TJ, et al (1997). Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-96.
19 Miao GY, Lu QM, Zhang XL (2007). Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol, 13, 1170-4.   DOI
20 Michels J, Johnson PW, Packham G (2005). Mcl-1. Int J Biochem Cell Biol, 37, 267-71.   DOI   ScienceOn
21 Montecucco A, Biamonti G (2007). Cellular response to etoposide treatment. Cancer Lett, 252, 9-18.   DOI   ScienceOn
22 Nakao K, Hamasaki K, Ichikawa T, et al (2006). Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep, 16, 389-92.   DOI
23 Paduano F, Villa R, Pennati M, et al (2006). Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther, 5, 179-86.   DOI   ScienceOn
24 Robak T, Wierzbowska A (2009). Current and emerging therapies for acute myeloid leukemia. Clin Ther, 31, 2349-70.   DOI   ScienceOn
25 Ryan BM, O'Donovan N, Duffy MJ (2009). Survivin: a new target for anti-cancer therapy. Cancer Treat Rev, 35, 553-62.   DOI   ScienceOn
26 Shan G (2010). RNA interference as a gene knockdown technique. Int J Biochem Cell Biol, 42, 1243-51.   DOI   ScienceOn
27 Song H, Xin XY, Xiao F, at al (2008). Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol, 136, 83-9.   DOI   ScienceOn
28 Wacheck V, Cejka D, Sieghart W, et al (2006). Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther, 5, 1348-54.   DOI
29 Yang M, Mattes J (2008). Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther, 117, 94-104.   DOI   ScienceOn
30 Zaffaroni N, Daidone MG (2002). Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat, 5, 65-72.   DOI   ScienceOn
31 Zaffaroni N, Pennati M, Daidone MG (2005). Survivin as a target for new anticancer interventions. J Cell Mol Med, 9, 360-72.   DOI   ScienceOn